Parabilis Medicines, Inc. (PBLS) Ownership
PBLS ownership summary
as of October 18, 2026- Institutions
- 82.5% of shares outstanding
- Insiders
- 7.03% of shares outstanding
- Shares outstanding
- 122.0M
- Float
- 82.1M shares available to trade
- Short interest
- 6.77% 8.3M shares short
- Days to cover
- 7.52 short interest up 35.6% vs prior month
- Institutions 82.45%
- Insiders 7.03%
- Other investors 10.52%
PBLS top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | RA Capital Management, LLC | 23.42% | 28.9M | $658.2M | +28.9M (0.0%) | June 30, 2026 |
| 2 | FMR Inc | 8.33% | 10.3M | $234.2M | +10.3M (0.0%) | June 30, 2026 |
| 3 | ARCH VENTURE CORP | 5.19% | 6.4M | $145.9M | +6.4M (0.0%) | June 30, 2026 |
| 4 | venBio Partners LLC | 4.26% | 5.3M | $119.8M | +5.3M (0.0%) | June 30, 2026 |
| 5 | Alphabet Inc | 3.98% | 4.9M | $111.9M | +4.9M (0.0%) | June 30, 2026 |
| 6 | Nextech Invest, Ltd. | 3.77% | 4.7M | $106.1M | +4.7M (0.0%) | June 30, 2026 |
| 7 | Cormorant Asset Management, LLC | 3.74% | 4.6M | $105.0M | +4.6M (0.0%) | June 30, 2026 |
| 8 | Regeneron Pharmaceuticals Inc | 3.37% | 4.2M | $94.8M | +4.2M (0.0%) | June 30, 2026 |
| 9 | Siren, L.L.C. | 2.42% | 3.0M | $68.1M | +3.0M (0.0%) | June 30, 2026 |
| 10 | Farallon Capital Management, L.L.C. | 1.92% | 2.4M | $53.9M | +2.4M (0.0%) | June 30, 2026 |
| 11 | Jupiter Topco LLC | 1.86% | 2.3M | $52.2M | +2.3M (0.0%) | June 30, 2026 |
| 12 | Frazier Life Sciences Management, L.P. | 1.55% | 1.9M | $43.7M | +1.9M (0.0%) | June 30, 2026 |
| 13 | Deerfield Management Co | 1.52% | 1.9M | $42.8M | +1.9M (0.0%) | June 30, 2026 |
| 14 | General Catalyst Group Management, LLC | 1.30% | 1.6M | $36.4M | +1.6M (0.0%) | June 30, 2026 |
| 15 | General Atlantic Llc | 1.25% | 1.5M | $35.0M | +1.5M (0.0%) | June 30, 2026 |
| 16 | Soleus Capital Management, L.P. | 1.19% | 1.5M | $33.3M | +1.5M (0.0%) | June 30, 2026 |
| 17 | Vanguard Portfolio Management, LLC | 1.05% | 1.3M | $29.6M | +1.3M (0.0%) | June 30, 2026 |
| 18 | Vanguard Capital Management, LLC | 0.94% | 1.2M | $26.3M | +1.2M (0.0%) | June 30, 2026 |
| 19 | JPMorgan Chase & Co | 0.84% | 1.0M | $23.7M | +1.0M (0.0%) | June 30, 2026 |
| 20 | Foresite Capital Management VI LLC | 0.81% | 999K | $22.7M | +999,044 (0.0%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 20 holders added 89.8M shares and 0 cut 0.
PBLS top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | T. Rowe Price Health Sciences | 1.76% | 2.2M | $49.4M | +1.7M (+346.2%) | August 31, 2026 |
| 2 | HBM Healthcare Investments AG Ord | 0.97% | 1.2M | $27.2M | +1.2M (0.0%) | June 30, 2026 |
| 3 | Vanguard MStar Total Stk Mkt Idx Invest | 0.91% | 1.1M | $25.5M | — | August 31, 2026 |
| 4 | iShares Russell 2000 ETF | 0.83% | 1.0M | $23.4M | +17,419 (+1.7%) | September 30, 2026 |
| 5 | Vanguard Small Cap Index | 0.66% | 810K | $18.4M | +364 (+0.0%) | August 31, 2026 |
| 6 | Fidelity Growth Company Fund | 0.39% | 479K | $10.9M | — | August 31, 2026 |
| 7 | JPMorgan Small Cap Growth A | 0.38% | 473K | $10.8M | −7,395 (−1.5%) | August 31, 2026 |
| 8 | Fidelity Select Biotechnology | 0.35% | 436K | $9.9M | +290,257 (+198.6%) | August 31, 2026 |
| 9 | Janus Henderson Hrzn Biotec E2 USD | 0.30% | 370K | $8.4M | +369,532 (0.0%) | June 30, 2026 |
| 10 | Janus Henderson Global Life Sciences D | 0.29% | 354K | $8.1M | +30,448 (+9.4%) | August 31, 2026 |
| 11 | Janus Henderson Glb Life Scn I2 USD | 0.28% | 351K | $8.0M | +38,000 (+12.1%) | August 31, 2026 |
| 12 | AB Small Cap Growth A | 0.26% | 324K | $7.4M | −4,692 (−1.4%) | August 31, 2026 |
| 13 | Janus Global Life Science AUSD | 0.25% | 313K | $7.1M | +312,976 (0.0%) | June 30, 2026 |
| 14 | MFS New Discovery I | 0.22% | 272K | $6.2M | — | August 31, 2026 |
| 15 | Vanguard MStar Small Cap Value Index | 0.21% | 257K | $5.9M | +329 (+0.1%) | August 31, 2026 |
| 16 | Vanguard MStar Small Cap Growth Indx Inv | 0.19% | 231K | $5.2M | −990 (−0.4%) | August 31, 2026 |
| 17 | iShares Russell 2000 Growth ETF | 0.18% | 224K | $5.1M | −283 (−0.1%) | September 30, 2026 |
| 18 | Janus Henderson Triton D | 0.16% | 193K | $4.4M | +135,264 (+235.8%) | August 31, 2026 |
| 19 | Schwab US Small-Cap ETF™ | 0.15% | 187K | $4.3M | +126 (+0.1%) | September 30, 2026 |
| 20 | Franklin Biotechnology Discv A(acc)USD | 0.14% | 172K | $3.9M | — | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
Who owns PBLS
Institutional investors own 82.5% of Parabilis Medicines's shares and insiders 7.03%. The largest holder is RA Capital Management, LLC with 23.42% of the shares (28.9M), as of June 30, 2026. Among the top 20 institutions, 20 added shares and 0 reduced their stake in the latest filings. Short interest is 6.77% of the float, or 7.52 days of average trading volume.
Related: PBLS analyst forecast, PBLS key metrics. See the PBLS stock overview for the latest quote and news.
PBLS ownership FAQ
Who owns the most Parabilis Medicines stock?
The largest shareholders of Parabilis Medicines are RA Capital Management, LLC (23.42%), FMR Inc (8.33%), ARCH VENTURE CORP (5.19%), venBio Partners LLC (4.26%), Alphabet Inc (3.98%).
What percentage of Parabilis Medicines is owned by institutions?
Institutions hold 82.5% of Parabilis Medicines's shares outstanding; insiders hold 7.03%.
Which funds own Parabilis Medicines?
The largest fund holders of Parabilis Medicines are T. Rowe Price Health Sciences (1.76%), HBM Healthcare Investments AG Ord (0.97%), Vanguard MStar Total Stk Mkt Idx Invest (0.91%), iShares Russell 2000 ETF (0.83%), Vanguard Small Cap Index (0.66%).
What is Parabilis Medicines's short interest?
8.3M shares of Parabilis Medicines were sold short, 6.77% of the float; at the average daily volume it would take 7.52 days to cover.
How many shares of Parabilis Medicines are outstanding?
Parabilis Medicines has 122.0M shares outstanding, of which 82.1M are in the public float.